← All trials
NCT06150859
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2021
- Primary completion
- Apr 15, 2024
- Completion date
- Jun 15, 2024
- First posted
- Nov 29, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 84
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beckley FoundationLead sponsor
- Badalona Hospital Germans Trias i PujolStudy director
- Beckley FoundationReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.